Author:
Xu Chang,Li Meng,Cai Xuwei,Yuan Shuanghu,Cao Jianzhong,Zhu Shuchai,Chen Ming,Bi Nan,Hu Xiao,Li Jiancheng,Zhou Wei,Wang Ping,Zhao Lujun,Liu Ningbo
Abstract
BackgroundThoracic radiotherapy (TRT) with concurrent chemotherapy is the standard treatment of limited-stage small-cell lung cancer (LS-SCLC). However, there is still a controversy surrounding the treatment strategy especially optimal dosing and fractionation schedule. Current practice patterns among Chinese oncologists are unknown.Materials and MethodsWe surveyed 212 Chinese oncologists using a questionnaire including 50 questions designed by experienced oncologists. Questions covered demographic data, treatment recommendations, and self-assessed knowledge of guidelines or key clinical trials for SCLC. The chi-square test and Fisher’s exact test were utilized to describe the result of the study.ResultsThe response rate was 97% (207/212). Of all the respondents, 69% preferred TRT QD, 29% preferred BID, and 2% chose HFRT. For those who prefer TRT QD, 72% preferred a total dose of 60 Gy, followed by 15% opting for 66 Gy, 12% for <60 Gy, and 1% for 70 Gy. Of those who prefer BID, 79% preferred a total dose of 45 Gy, with 4% choosing 30 Gy, 8% choosing 50 Gy, 7% choosing 54 Gy, and 2% choosing >54 Gy. Regarding PCI, 82% of participants believed that PCI should be performed when treatment is completed and 13% believed that PCI should begin immediately after concurrent chemoradiotherapy. As for other therapies, 26% of participants choose concurrent anti-angiogenic therapy during SCLC treatment, and 49% recommended small-molecule TKI as the main anti-angiogenic therapy.ConclusionSubstantial variation exists in how Chinese oncologists approach TRT dosing and fractionation for LS-SCLC. Almost 70% of respondents reported administering TRT QD more often in daily work. The most common doses were 60 Gy QD and 45 Gy BID.
Reference30 articles.
1. Small-Cell Lung Cancer;Van Meerbeeck;Lancet,2011
2. Clinical Profiles and Trend Analysis of Newly Diagnosed Lung Cancer in a Tertiary Care Hospital of East China During 2011-2015;Wang;J Thorac Dis,2017
3. Unravelling the Biology of SCLC: Implications for Therapy;Sabari;Nat Rev Clin Oncol,2017
4. Twice-Daily Compared With Once-Daily Thoracic Radiotherapy in Limited Small-Cell Lung Cancer Treated Concurrently With Cisplatin and Etoposide. Phase III Comparison of Twice-Daily Split Course Irradiation Versus Once-Daily Irradiation for Patients With Limited Stage Small-Cell Lung Carcinoma;Proudhom;Cancer Radiother,2000
5. Concurrent Once-Daily Versus Twice-Daily Chemoradiotherapy in Patients With Limited-Stage Small-Cell Lung Cancer (CONVERT): An Open-Label, Phase 3, Randomised, Superiority Trial;Faivre-Finn;Lancet Oncol,2017
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献